š Share this article Patients Coming Off Weight-Loss Jabs Put On Pounds Four Times Faster Than Those on Conventional Diets Weight management often requires long-term strategies. Fresh analysis indicates that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs. Published data in a major health publication shows that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of 0.8 kg per month after stopping. "Users using these medications must be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb. Such speed of recovery suggests a reversion to pre-treatment weight within about one and a half years. Comparing Therapies The study, which looked at 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods. The team emphasize that individuals who lose weight through dieting typically see a slower creep backāperhaps 100 grams monthlyāonce they finish. Explaining the Fast Rebound Nutrition scientists suggest the mechanism of the jabs explains the accelerated weight return. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness. "Artificially providing the hormone concentrations several times higher than normal might result in the system to produce less of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher. "Stopping of this hormone supplement means appetite is no longer kept in check, making binge eating far more likely." An Ongoing Disease? Health authorities recommend the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. Professionals argue that, given the high risk of weight regain, the treatment is often life-long. This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the persistent nature of excess weight," akin to managing conditions like hypertension. User Accounts People who have discontinued the medication describe a intense resurgence of appetite. "I experienced a trigger activating and you're instantly starving," described an individual. This challenge is worsened if patients have not adopted permanent dietary or behavioural changes during treatment. Significant Use Figures suggest that a significant number of people in the UK have tried these injections in the past year, with demand being substantial. Use is greater among females than men. The 40s and 50s age group shows the highest usage rates. Many access the medications through private healthcare rather than public health services. In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and long-term success hinges on ongoing behavioural support.
Weight management often requires long-term strategies. Fresh analysis indicates that individuals who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle programs. Published data in a major health publication shows that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of 0.8 kg per month after stopping. "Users using these medications must be cognizant of the potential of rapid rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb. Such speed of recovery suggests a reversion to pre-treatment weight within about one and a half years. Comparing Therapies The study, which looked at 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods. The team emphasize that individuals who lose weight through dieting typically see a slower creep backāperhaps 100 grams monthlyāonce they finish. Explaining the Fast Rebound Nutrition scientists suggest the mechanism of the jabs explains the accelerated weight return. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness. "Artificially providing the hormone concentrations several times higher than normal might result in the system to produce less of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher. "Stopping of this hormone supplement means appetite is no longer kept in check, making binge eating far more likely." An Ongoing Disease? Health authorities recommend the injections for individuals with weight-linked health risks, alongside recommended diet and exercise modifications. Professionals argue that, given the high risk of weight regain, the treatment is often life-long. This perspective is echoed by pharmaceutical companies, who state that the results "emphasize the persistent nature of excess weight," akin to managing conditions like hypertension. User Accounts People who have discontinued the medication describe a intense resurgence of appetite. "I experienced a trigger activating and you're instantly starving," described an individual. This challenge is worsened if patients have not adopted permanent dietary or behavioural changes during treatment. Significant Use Figures suggest that a significant number of people in the UK have tried these injections in the past year, with demand being substantial. Use is greater among females than men. The 40s and 50s age group shows the highest usage rates. Many access the medications through private healthcare rather than public health services. In conclusion, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and long-term success hinges on ongoing behavioural support.